Ramosetron OD Tablet and Postdischarge Nausea and Vomiting

Phase 4 Unknown 138 enrolled Seoul National University Hospital

Non-randomizedParallel-groupDouble-blindPrevention

Summary

Postoperative nausea and vomiting after general anesthesia is one of the common anesthetic complications. If the patient is discharged from the hospital after surgery, proper treatment may be delayed or impossible if nausea and vomiting occurred. Thus, it is necessary to prevent these symptoms beforehand. Patients who underwent day-surgery will be treated with prophylactic ramosetron orally disintegrating tablets to determine whether the frequency of nausea and vomiting is decreased when the patient returned home after discharge.

Timeline

Start: 2020-05-12
Primary completion: 2022-02-28
Completion: 2022-02-28

Outcome

Met primary endpoint

paper incidence (13% vs. 33%, P = 0.008) and severity (P = 0.011) of nausea between the ramosetron and the control groups PMID 35546414 ↗

Publications

Shin HJ, Park YH, Chang M, Chae YJ, Lee HT, Lee OH, Min SK, Do SH. Effects of ramosetron orally disintegrating tablets on the prophylaxis of post-discharge nausea and/or vomiting in female patients undergoing day surgery under general anesthesia: a randomized controlled trial. Perioper Med (Lond). 2022 May 12;11(1):17. doi: 10.1186/s13741-022-00251-6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ramosetron	Small molecule	0.1 mg	Oral

Indications

No indication recorded.